Colin Hill is Chairman and CEO of Gene Network Sciences. In this role, Hill develops the strategic roadmap and vision for the company and oversees the leadership of business operations. Hill brings years of hands-on scientific experience to his role, with expertise in the areas of computational physics and systems biology. Colin Hill was recently named to MIT Technology Review's TR100 list of the top innovators in the world under the age of 35, and was also selected by Black Enterprise as the winner of the 2004 "Rising Star" small business award. Colin Hill graduated from Virginia Tech with a degree in physics and went on to earn masters degrees in physics from McGill and Cornell Universities.
In cancer drug development, the process of inferring the model with reverse engineering and simulating it is core to what we do. So here we are talking about data coming from a pharmaceutical company. We run it through our software to discover the network connectivity and the parameters and then u...(Full transcript available to logged in subscribers.).
Register & Subscribe
Login